Prospects for a personalized peptide vaccine against lung cancer
Author:
Affiliation:
1. Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Japan
2. Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan
3. Cancer Vaccine Center, Kanagawa Cancer Center, Yokohama, Japan
Funder
JSPS KAKENHI
AMED
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmacology,Molecular Medicine,Immunology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14760584.2019.1635461
Reference72 articles.
1. Lung cancer
2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immunogenic dead cells engineered by the sequential treatment of ultraviolet irradiation/cryo-shocking for lung-targeting delivery and tumor vaccination;Biomaterials Science;2024
2. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy;Journal of Nanobiotechnology;2023-09-26
3. Nano-immunotherapy for lung cancer;Nano TransMed;2023-03
4. The role of immunotherapy in treating lung cancer: current status and future perspective;Future Drug Discovery;2021-12
5. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?;Journal of Thoracic Oncology;2021-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3